
Daiichi Sankyo and MSD withdraw US application for lung cancer BLA
Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed DXd antibody drug conjugate (ADC) patritumab deruxtecan, intended for treating non-small cell lung cancer (NSCLC). The withdrawal …